Pds Biotechnology CORP

PDS Biotechnology Corporation received a deficiency letter from Nasdaq for failing to meet the minimum $1.00 bid price requirement for its common stock.

PDS Biotechnology Corporation closed a $6 million promissory note and established a $50 million at-the-market offering program with YA II PN, LTD. and its affiliate Yorkville Securities, LLC.

PDS Biotechnology Corporation announced its 2026 Annual Meeting of Stockholders will be held on August 10, 2026, with a June 25, 2026 deadline for stockholder proposals.

PDS Biotechnology Corporation announced it has regained compliance with Nasdaq's minimum bid price requirement, closing a deficiency matter.

PDS Biotech reports Q1 2026 financial results, highlighting clinical advancements in cancer immunotherapies and a reduced net loss.

PDS Biotechnology has entered into a $6 million securities purchase agreement and initiated an at-the-market offering program while retiring existing senior secured debt.

PDS Biotechnology Corporation reported a reduced net loss for Q3 2025, advanced multiple immunotherapy clinical trials, but raised substantial doubt about its ability to continue as a going concern.

PDS Biotechnology reported an increased net loss for Q2 2025 and a going concern warning, despite advancing its immunotherapy pipeline with positive clinical trial data and new financing.

PDS Biotechnology Corporation announces its financial results for the first quarter of 2025, detailing ongoing clinical trials and recent financing activities.

PDS Biotechnology reported a net loss of $10.7 million for the third quarter of 2024, while continuing to advance its clinical programs.

PDS Biotechnology Corp. reports a net loss of $8.3 million for the second quarter of 2024, while highlighting progress in its clinical trials and pipeline development.

PDS Biotechnology reported a net loss of $10.6 million for the first quarter of 2024, while highlighting progress in its clinical trials and pipeline development.

PDS Biotechnology Corporation has filed an amendment to its 2025 Annual Report on Form 10-K, primarily to include Part III disclosures regarding directors, executive officers, compensation, and related matters.

PDS Biotechnology Corporation's 2025 annual report highlights significant progress in its oncology pipeline with promising clinical trial results for PDS0101 and PDS01ADC, despite ongoing financial losses and a going concern warning.

PDS Biotechnology Corporation files its 10-K report for the year ended December 31, 2024, detailing its financial results and progress in developing its Versamune and Infectimune immunotherapy platforms.

PDS Biotechnology Corporation's 10-K filing details its clinical-stage immunotherapy pipeline, financial status, and strategic direction for 2023.

PDS Biotechnology Corp's President and CEO, Frank Bedu-Addo, was granted 548,782 employee stock options with a $0.98 exercise price, vesting over four years.

PDS Biotechnology's Chief Scientific Officer, Gregory Conn, was granted 150,000 employee stock options with an exercise price of $0.98, vesting over four years.

PDS Biotechnology Corp's Chief Medical Officer, Kirk V. Shepard, was granted 300,000 employee stock options with a $0.98 exercise price and a 10-year term.

PDS Biotechnology Corp's Chief Financial Officer, Lars Boesgaard, was granted 300,000 employee stock options with an exercise price of $0.98, vesting over four years.

PDS Biotechnology Corp's Senior VP and General Counsel, Spencer D. Brown, was granted 300,000 employee stock options with a $0.98 exercise price.

PDS Biotechnology Corp's Chief Operating Officer, Stephan Toutain, was granted 300,000 employee stock options with an exercise price of $0.98.

PDS Biotechnology Corporation has issued its proxy statement for the 2026 Annual Meeting, seeking approval for director elections, an increase in authorized common stock, and executive compensation.

PDS Biotechnology amends its proxy statement to revise the description of its total equity overhang and historical and projected burn rate in connection with Proposal 2, concerning the amendment of the 2014 Equity Incentive Plan.

PDS Biotechnology amends its proxy statement to revise details regarding equity overhang and burn rate related to the proposed amendment of its 2014 Equity Incentive Plan.

PDS Biotechnology Corporation has filed a definitive proxy statement with the SEC.

PDS Biotechnology Corporation is seeking stockholder approval to amend its 2014 Equity Incentive Plan to increase the number of shares available for issuance at the Annual Meeting of Stockholders to be held on June 11, 2025.

PDS Biotechnology Corporation has filed a definitive proxy statement with the SEC.

Armistice Capital, LLC and Steven Boyd report a 4.99% passive beneficial ownership stake in PDS Biotechnology Corp.

Armistice Capital, LLC and Steven Boyd have jointly disclosed a passive beneficial ownership of 9.99% in PDS Biotechnology Corp's common stock as of March 31, 2025.